Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer

Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. The RAS pathway is activated in more than 55% of CRC and has been targeted for therapeutic intervention with MEK inhibitors. Unfortunately, many patients have de novo resistance, or can develop resistance to th...

Full description

Bibliographic Details
Main Authors: Thomas Benjamin Davis, Shilpa Gupta, Mingli Yang, Lance Pflieger, Malini Rajan, Heiman Wang, Ramya Thota, Timothy J. Yeatman, Warren Jackson Pledger
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
colorectal cancer (CRC)
drug resistance
biomarkers
drugs sensitivity selection
MEK inhibition
SRC inhibition
Online Access:https://www.mdpi.com/2072-6694/14/6/1451

Internet

https://www.mdpi.com/2072-6694/14/6/1451

Similar Items